-BofA, Barclays to handle BioMarin's share issue.
M2 EQUITYBITES-May 31, 2012--BofA, Barclays to handle BioMarin's share issue(C)2012 M2 COMMUNICATIONS http://www.m2.com
31 May 2012 - Bank of America Merrill Lynch and Barclays have been appointed to manage the sale of 6.5m common shares by BioMarin Pharmaceutical Inc (NASDAQ:BMRN), the US biopharmaceuticals company said on Wednesday.
The underwriters have been granted an option to buy an additional 650,000 common shares in the company within 30 days of the offering.
The stock will be offered at prevailing market prices or othewise from time to time through the Nasdaq Global Select Market, the over-the-counter market, negotiated transactions or otherwise.
The shares will be issued by means of a preliminary prospectus supplement to be filed by the company with the US Securities and Exchange Commission pursuant to a registration statement previously filed with and declared effective by the regulator.
BioMarin, based in Novato, California, specialises in the development and commercialisation of pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America and the rest of the world. As of December 31, 2011, its product portfolio included four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase) for mucopolysaccharidosis VI, Kuvan (sapropterin dihydrochloride) for phenylketonuria, Aldurazyme (laronidase) for mucopolysaccharidosis I and Firdapse (amifampridine phosphate) for the treatment of Lambert Eaton Myasthenic Syndrome. The company was founded in 1996.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||May 31, 2012|
|Previous Article:||-BOCI, GF Securities handle Beijing Capital Development's debt offer.|
|Next Article:||-HSH Nordbank issues new mortgage covered bond.|